权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Glomerular podocyte injury in lifestyle-related disease : elucidation of its mechanism and establishment of novel therapeutic strategy to inhibit proteinuria

生活方式相关疾病中的肾小球足细胞损伤：阐明其机制并建立抑制蛋白尿的新治疗策略

基本信息

批准号：
17590820
负责人：
NAGASE Miki
金额：
$ 2.37万
依托单位：
The University of Tokyo
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2005
资助国家：
日本
起止时间：
2005 至 2006
项目状态：
已结题

项目摘要

In this study, we demonstrated the involvement of podocyte injury in the pathogenesis of proteinuria and glomerulosclerosis in Dahl salt hypertensive rats, which were effectively ameliorated by selective aldosterone blocker eplerenone. Aldosterone-infused rats fed a high salt diet demonstrated podocyte injury and massive proteinuria, which was completely reversed by eplerenone. Reduction of systemic blood pressure by hydralazine failed to prevent podocyte injury and proteinuria, whereas antioxidant tempol reduced the injury. Mineralocorticoid receptor was detected in the podocytes in vivo and in vitro, and aldosterone caused induction of its effector kinase Sgk1, activation of NADPH oxidase and generation of reactive oxygen species. We also demonstrated enhanced proteinuria and podocyte injury in metabolic syndrome model SHR/NDmcr-cp (SHR/cp) compared with non-obese SHR. Serum aldosterone level and renal Sgk1 expression were elevated in SHR/cp. Eplerenone as well as tempol effectively improved podocyte damage and proteinuria. As for the mechanisms of aldosterone excess, visceral adipocytes isolated from SHR/cp secreted substances that stimulate aldosterone production in adrenocortical cells. Adipocytes from non-obese SHR did not show such activity. Our data suggest that adipocyte-derived factors might contribute to the aldosterone excess, podocyte injury, and proteinuria in this model. Recent studies indicated that podocyte injury plays a pathogenetic role also in diabetic, hypertensive, and obesity-related glomerulopathy. Thus, aldosterone blockage can be an excellent therapeutic strategy for the treatment of podocyte injury, proteinuria, cardiovascular and renal complications in these conditions. We also demonstrated the protective actions of statins and adrenomedullin against podocyte injury.

在这项研究中，我们证明足细胞损伤参与了Dahl盐高血压大鼠蛋白尿和肾小球硬化的发病机制，选择性醛固酮阻滞剂eplerenone有效地改善了这一过程。注射醛固酮的大鼠饲喂高盐饮食，表现出足细胞损伤和大量蛋白尿，依普利酮完全逆转。羟嗪降低全身血压不能防止足细胞损伤和蛋白尿，而抗氧化丹泊能减轻损伤。在体内和体外足细胞中检测到矿盐皮质激素受体，醛固酮诱导其效应激酶Sgk1，激活NADPH氧化酶，产生活性氧。我们还发现，与非肥胖的SHR相比，代谢综合征模型SHR/NDmcr-cp （SHR/cp）的蛋白尿和足细胞损伤增加。SHR/cp组血清醛固酮水平和肾脏Sgk1表达升高。eperenone和tempol有效改善足细胞损伤和蛋白尿。至于醛固酮过量的机制，从SHR/cp分离的内脏脂肪细胞分泌刺激肾上腺皮质细胞醛固酮产生的物质。非肥胖SHR的脂肪细胞没有表现出这种活性。我们的数据表明，脂肪细胞衍生因子可能导致该模型中醛固酮过量、足细胞损伤和蛋白尿。最近的研究表明足细胞损伤在糖尿病、高血压和肥胖相关的肾小球病变中也起着致病作用。因此，醛固酮阻断是治疗足细胞损伤、蛋白尿、心血管和肾脏并发症的一种极好的治疗策略。我们还证明了他汀类药物和肾上腺髓质素对足细胞损伤的保护作用。